Phase 2/3 study of ELND005 did not meet primary efficacy endpoint
24 June 2015 | By Victoria White
A Phase 2/3 clinical study of ELND005 in agitation and aggression in patients with Alzheimer's disease (AD) did not meet its primary efficacy endpoint...
































